Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study.

Xi DingWei-Jing ZhangRui YouXiong ZouZhi-Qiang WangYan-Feng OuyangLan PengYou-Ping Liu Chong-Yang DuanQi YangChao LinYu-Long XieSi-Yuan ChenYong-Long LiuChen-Mei GuRuo-Qi XiePei-Yu HuangMing-Huang HongYi-Jun HuaMing-Yuan Chen

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

Camrelizumab plus apatinib had promising antitumor activity in patients with refractory recurrent/metastatic NPC who failed first-line therapy. Moderate to severe TRAEs were experienced by 58.6%, including nasopharyngeal necrosis associated with local recurrence and a history of reirradiation.

Keyphrases

phase ii study
squamous cell carcinoma
small cell lung cancer
locally advanced
open label
early onset
high intensity
clinical trial
placebo controlled
drug induced
mesenchymal stem cells